Literature DB >> 3965930

Characterization of specific binding sites for [3H](d)-N-allylnormetazocine in rat brain membranes.

Y Itzhak, J M Hiller, E J Simon.   

Abstract

Binding of [3H](d)-N-allylnormetazocine ([3H](d)-NANM) to rat brain membranes is stereospecific, reversible, and saturable (Bmax = 260 fmol/mg of protein) and manifests moderately high affinity (Kd = 20 nM). The rank order of potency among opioidbenzomorphans and phencyclidine (PCP) analogs for competition for [3H](d)-NANM-binding sites is as follows: (d)-NANM = PCP-3-OH greater than (d)-cyclazocine greater than N-ethylphenylcyclohexylamine greater than PCP greater than (l)-cyclazocine = dextrorphan greater than (d/l)-ethylketocyclazocine greater than (d/l)-bremazocine greater than (1)-NANM greater than 1-phenylcyclohexylamine greater than levorphanol. Other opioid ligands, relatively selective for each of the types of opioid binding sites other than sigma, such as morphine (mu), H-Tyr-D-Ala(Me)Phe-NH-CH2-OH (mu), D-Ala2-D-Leu5-enkephalin (delta), tifluadom (kappa), and U 50488 (kappa) as well as etorphine and naloxone were all unable to compete with [3H](d)-NANM for specific binding even at a concentration of 1 microM. Regional distribution studies of [3H](d)-NANM-binding sites show high density in the hippocampus, thalamus, hypothalamus, and amygdala and low density in cerebellum and nonfrontal neocortex membranes of the rat brain. These binding sites are very sensitive to protein-modifying enzymes and reagents such as trypsin and N-ethylmaleimide and to heat denaturation. These results provide direct biochemical evidence for the existence of distinct (d)-NANM-binding sites in rat brain. In addition, this study supports the view that PCP and several of its analogues and the dextrorotatory isomers of psychotomimetic benzomorphans may act at a common recognition site in rat central nervous system.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3965930

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

Review 1.  Sigma receptors: potential targets for a new class of antidepressant drug.

Authors:  James A Fishback; Matthew J Robson; Yan-Tong Xu; Rae R Matsumoto
Journal:  Pharmacol Ther       Date:  2010-05-11       Impact factor: 12.310

Review 2.  Opioid receptors and pain.

Authors:  R Dirksen
Journal:  Pharm Weekbl Sci       Date:  1990-04-27

3.  Inhibition of (+)[3H]SKF 10,047 binding to rat brain membranes by FAB fragments from a monoclonal antibody directed against the opioid receptor.

Authors:  C B Tyler; J M Bidlack
Journal:  Neurochem Res       Date:  1988-08       Impact factor: 3.996

4.  Effects of phencyclidine, SKF 10,047 and related psychotomimetic agents on N-methyl-D-aspartate receptor mediated synaptic responses in rat hippocampal slices.

Authors:  E J Coan; G L Collingridge
Journal:  Br J Pharmacol       Date:  1987-07       Impact factor: 8.739

5.  Effects of the psychotomimetic benzomorphan N-allylnormetazocine (SKF 10,047) on prepulse inhibition of startle in mice.

Authors:  Adam L Halberstadt; James Hyun; Michael A Ruderman; Susan B Powell
Journal:  Pharmacol Biochem Behav       Date:  2016-05-26       Impact factor: 3.533

6.  Discriminative stimulus properties of (+)-N-allylnormetazocine in the rat: correlations with (+)-N-allylnormetazocine and phencyclidine receptor binding.

Authors:  G F Steinfels; S W Tam; L Cook
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

7.  A role played by sigma receptors in the conditioned suppression of motility in mice.

Authors:  T Nabeshima; H Kamei; T Kameyama
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors.

Authors:  Kazuki Terada; Keisuke Migita; Yukari Matsushima; Yumi Sugimoto; Chiaki Kamei; Taichi Matsumoto; Masayoshi Mori; Kazuhisa Matsunaga; Jiro Takata; Yoshiharu Karube
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.